IBO
AMEXImpact BioMedical Inc.
News · 26 weeks11-100%
2025-12-142026-06-07
Mix790d
- SEC Filings4(57%)
- Insider2(29%)
- Other1(14%)
Latest news
25 items- SECSEC Form 10-Q filed by Impact BioMedical Inc.10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form 144 filed by Impact BioMedical Inc.144 - IMPACT BIOMEDICAL INC. (0001834105) (Subject)
- SECSEC Form S-8 POS filed by Impact BioMedical Inc.S-8 POS - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form S-8 POS filed by Impact BioMedical Inc.S-8 POS - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- PRImpact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger PlansHOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi & Co., CPAs, P.C. that contains a "going concern" qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company's financial statements for the year ended December 31, 2025. Again, this announcement does not represent any change or amendment to the Company's finan
- INSIDERSEC Form 4 filed by Macko Todd D4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
- INSIDERSEC Form 4 filed by Grady Jason4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
- SECSEC Form 10-K filed by Impact BioMedical Inc.10-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECImpact BioMedical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- INSIDERLarge owner Dss, Inc. sold $88,006 worth of shares (161,000 units at $0.55), decreasing direct ownership by 23% to 545,024 units (SEC Form 4)4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
- SECSEC Form DEF 14C filed by Impact BioMedical Inc.DEF 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form PRE 14C filed by Impact BioMedical Inc.PRE 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form 10-Q filed by Impact BioMedical Inc.10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECImpact BioMedical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECImpact BioMedical Inc. filed SEC Form 8-K: Other Events8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form DEF 14A filed by Impact BioMedical Inc.DEF 14A - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form DEF 14C filed by Impact BioMedical Inc.DEF 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form PRE 14C filed by Impact BioMedical Inc.PRE 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- PRImpact Biomedical Inc (IBO) Announces 3F™ US Patent IssueHOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled "Composition and Method of Controlling Infectious Diseases with Functional Fragrances," developed within IBO's 3F™ technology platform. This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by plants, with potential application as an antibacterial or antiviral agent. This patent will expire on December 7, 2038. This expands Impact Biomedical's 3F™ patent estate which include
- SECSEC Form 10-Q filed by Impact BioMedical Inc.10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form DEF 14C filed by Impact BioMedical Inc.DEF 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form PRE 14C filed by Impact BioMedical Inc.PRE 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- PRDr Ashleys Limited and Impact BioMedical Inc. Announce Strategic MergerA Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ("Dr Ashleys"), and Impact BioMedical Inc. ("Impact BioMedical") (NYSE:IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American ("Impact BioMedical", together with Dr Ashleys, the "Parties"), are pleased to announce the execution of a merger and share exchange agreement (the "Merger Agreement") on June 21, 2025 to enter into a strategic merger transaction (the "Transaction"). Upon closing of the Transaction, Dr. Ashleys will acquire Impact B
- SECImpact BioMedical Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form 10-Q filed by Impact BioMedical Inc.10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
IBO FAQ
5 questionsWhere does IBO stock trade?
Impact BioMedical Inc. (IBO) is listed on AMEX.What sector and industry is IBO in?
Impact BioMedical Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Impact BioMedical Inc. go public?
Impact BioMedical Inc. (IBO) completed its IPO in 2024.What companies are similar to IBO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IBO side-by-side with any of them on Quantisnow.How can I track IBO on Quantisnow?
Quantisnow aggregates Impact BioMedical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IBO to receive live email and push alerts on every new disclosure.